Given the small market cap, the valuation for this stock is definitely there, it's lack of growth that stagnated the share price, let's see if this improves on 31 Jan.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025